Disc Medicine appoints Nadim Ahmed to board of directors

WATERTOWN, Mass. - Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company with a market capitalization of $1.97 billion, has appointed Nadim Ahmed to its Board of Directors, according to a company press release issued Monday. According to InvestingPro data, the company’s stock has shown strong momentum, delivering a 20.65% return over the past year despite broader market volatility.

Ahmed currently serves as President and Chief Executive Officer of Cullinan Therapeutics, a biopharmaceutical company developing clinical-stage programs focused on oncology and autoimmune diseases.

The new board member brings more than 25 years of leadership experience in development and commercialization roles. Prior to joining Cullinan Therapeutics, Ahmed worked at Bristol Myers Squibb as President, Hematology and at Celgene Corporation as President, Global Hematology & Oncology.

John Quisel, President and Chief Executive Officer of Disc Medicine, stated that Ahmed’s "track record of successful drug launches and deep expertise in hematological diseases will be invaluable" as the company advances bitopertin towards commercialization in erythropoietic protoporphyria (EPP).

Ahmed holds a Master of Science degree from Loughborough University, UK and a Bachelor of Science degree from University College London, UK.

Disc Medicine is a clinical-stage biopharmaceutical company focused on developing treatments for hematologic diseases. The company is working on therapeutic candidates targeting heme biosynthesis and iron homeostasis.

The company expects several catalysts in the coming months, including a potential New Drug Application (NDA) filing for bitopertin in EPP, according to the press release statement.

In other recent news, Disc Medicine has been the focus of several analyst evaluations and corporate developments. Morgan Stanley initiated coverage on Disc Medicine with an Overweight rating, citing the potential for bitopertin to reach the market sooner than expected. They project a 2026 launch for bitopertin with significant sales potential. H.C. Wainwright reaffirmed its Buy rating and $118 target, highlighting the company’s progress with bitopertin for Erythropoietic Protoporphyria and the potential of DISC-0974 in treating myelofibrosis. BMO Capital maintained its Outperform rating and noted Disc Medicine’s ongoing progress in its pipeline, including a scheduled bitopertin NDA submission for 2025.

Additionally, Disc Medicine held its Annual Meeting of Stockholders, where shareholders elected three Class II directors and approved executive compensation plans. The company also ratified the appointment of Ernst & Young LLP as its independent accounting firm for the fiscal year 2025. These developments reflect ongoing strategic efforts and investor confidence in Disc Medicine’s future.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.